NEWS BRIEF
Results favorable for B-cell non-Hodgkin's lymphoma
Rituxan (rituximab), a drug co-developed by San Francisco-based Genentech, San Diego-based IDEC, F. Hoffmann-La Roche of Switzerland, and Zenyaku Kogyo of Japan has shown promise in battling combat relapsed or refractory low-grade or follicular CD20- positive B-cell non-Hodgkin’s lymphoma. The FDA approved the drug for marketing in November 1997.
The trial, conducted at 31 U.S. sites, showed a 48% overall response rate in 166 intent-to-treat patients. Of these responses, 10 were complete and 70 were partial. And 56 of the 75 patients who did not achieve a complete or partial response reported a net decrease of measurable disease.
The projected median time to progression for responders was 13 months, with a median follow-up duration of 11.8 months. Side effects were mild, with fever and chills the most common events. Only 12% of patients had grade 3 toxicities, and 3% had grade 4 toxicities. Final study data will be re-analyzed after all the patients have relapsed.
Rituxan is given over a 22-day period in four infusions, typically in an outpatient setting. Special handling is not required of the therapy or patient.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content